CN100439365C - 用作蛋白激酶抑制剂的化合物和组合物 - Google Patents

用作蛋白激酶抑制剂的化合物和组合物 Download PDF

Info

Publication number
CN100439365C
CN100439365C CNB2004800245751A CN200480024575A CN100439365C CN 100439365 C CN100439365 C CN 100439365C CN B2004800245751 A CNB2004800245751 A CN B2004800245751A CN 200480024575 A CN200480024575 A CN 200480024575A CN 100439365 C CN100439365 C CN 100439365C
Authority
CN
China
Prior art keywords
methyl
phenyl
pyrrolo
pyrimidine
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800245751A
Other languages
English (en)
Chinese (zh)
Other versions
CN1842529A (zh
Inventor
丁强
N·S·格雷
李兵
刘异
宇野哲郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of CN1842529A publication Critical patent/CN1842529A/zh
Application granted granted Critical
Publication of CN100439365C publication Critical patent/CN100439365C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB2004800245751A 2003-08-28 2004-08-27 用作蛋白激酶抑制剂的化合物和组合物 Expired - Fee Related CN100439365C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49853203P 2003-08-28 2003-08-28
US60/498,532 2003-08-28

Publications (2)

Publication Number Publication Date
CN1842529A CN1842529A (zh) 2006-10-04
CN100439365C true CN100439365C (zh) 2008-12-03

Family

ID=34519982

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800245751A Expired - Fee Related CN100439365C (zh) 2003-08-28 2004-08-27 用作蛋白激酶抑制剂的化合物和组合物

Country Status (9)

Country Link
US (2) US7338957B2 (https=)
EP (1) EP1658290A4 (https=)
JP (1) JP2007504159A (https=)
CN (1) CN100439365C (https=)
AU (1) AU2004283093B2 (https=)
BR (1) BRPI0414049A (https=)
CA (1) CA2536535A1 (https=)
MX (1) MXPA06002347A (https=)
WO (1) WO2005039486A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US8183248B2 (en) * 2005-05-13 2012-05-22 Irm Llc Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
JP5680850B2 (ja) * 2006-03-30 2015-03-04 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｕｒｔ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｅｄｉｎｂｕｒｇｈ キナーゼインヒビターを含む培養培地およびその使用
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US20090286803A1 (en) 2006-04-07 2009-11-19 Manley Paul W Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides
WO2009042013A1 (en) 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
ES2424977T3 (es) * 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
EA019869B1 (ru) * 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
JP2011510004A (ja) * 2008-01-22 2011-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング タンパク質キナーゼ阻害剤及びその使用
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US8728763B2 (en) 2009-08-11 2014-05-20 Response Genetics Methods, primers, probes and kits useful for the detection of BRAF mutations
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1335849A (zh) * 1998-09-18 2002-02-13 巴斯福股份公司 作为蛋白激酶抑制剂的吡咯并嘧啶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
CO5271715A1 (es) * 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1335849A (zh) * 1998-09-18 2002-02-13 巴斯福股份公司 作为蛋白激酶抑制剂的吡咯并嘧啶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Activation of tyrosine Kinases in cancer. VLAHOVIC G et al.Oncologist,Vol.8 No.6. 2003 *

Also Published As

Publication number Publication date
JP2007504159A (ja) 2007-03-01
US20080108616A1 (en) 2008-05-08
WO2005039486A3 (en) 2006-03-16
MXPA06002347A (es) 2006-05-19
CA2536535A1 (en) 2005-05-06
AU2004283093B2 (en) 2009-02-26
US20050159391A1 (en) 2005-07-21
US7338957B2 (en) 2008-03-04
BRPI0414049A (pt) 2006-10-24
EP1658290A4 (en) 2009-04-15
WO2005039486A2 (en) 2005-05-06
EP1658290A2 (en) 2006-05-24
CN1842529A (zh) 2006-10-04
AU2004283093A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
KR102531036B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CN104781252B (zh) 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物
EP2699564B1 (en) Substituted pyrimidinyl-pyrroles active as kinase inhibitors
CA2779105C (en) Kinase inhibitors
JP4917041B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
CN115626919A (zh) 哒嗪基噻唑甲酰胺类化合物
CN101500574A (zh) 用作蛋白激酶抑制剂的化合物和组合物
CN101282975A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN104884454A (zh) 用作IL-12、IL-23和/或IFNα应答调节剂的酰胺取代的杂环化合物
CN101175753A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CA2619365A1 (en) Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
KR102477063B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
CN101166732B (zh) 氰基吡啶衍生物及其作为药物的应用
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
JP2022533182A (ja) タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
CN109810098A (zh) 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂
CN101208338A (zh) 氮杂苯并咪唑衍生物，它们的制备以及作为抗癌剂的应用
ES2418457T3 (es) Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3)
CN101056632B (zh) 用作蛋白激酶抑制剂的化合物和组合物
WO2019109647A1 (zh) 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
JP2009501176A (ja) グリコーゲンシンターゼキナーゼ３阻害薬としてのピリダジン化合物
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081203

Termination date: 20110827